This Article Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garipidou, V. Articles by Tziomalos, K. Search for Related Content PubMed PubMed Citation Articles by Garipidou, V. Articles by Tziomalos, K.

Letter to the Editor

Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate

Hematology Section of Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

Correspondence: Correspondence: Konstantinos Tziomalos, M.D., 63 Solonos Street, Thessaloniki, 54248, Greece. Telephone: 00-30-231-082-3487; Fax: 00-30-231-099-2834; e-mail: ktziomalos{at}yahoo.com

Key Words. Multiple myeloma • Chronic myeloid leukemia • Imatinib mesylate • Erk1/2 mitogen-activated protein kinases

The co-occurrence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is an extremely rare event and is considered to be coincidental [1,2]. Imatinib mesylate (Gleevec^®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, http://www.pharma.us.novartis.com) is the new gold standard for the treatment of CML, particularly in patients who are not candidates for transplantation [3]. We report the case of a patient who was initially diagnosed with CML and developed MM after 7 months of treatment with imatinib mesylate.

A 68-year-old male was diagnosed with CML in December of 2001. Cytogenetic analysis revealed the presence of the Philadelphia (Ph¹) chromosome: 46, XY, t(9;14;22)(q34;q24;q11). BCR/ABL mRNA transcripts were detected with reverse transcription polymerase chain reaction (RT-PCR). The patient received interferon alpha, and after 10 months, a bone marrow smear revealed normal cellularity, normal maturation of all series, 2% mature plasma cells, and no increase in blast cells. Nevertheless, cytogenetic analysis showed no cytogenetic response. Therefore, on January of 2003, therapy was switched to imatinib mesylate (400 mg once daily), and after 7 months, a bone marrow smear disclosed normal cellularity and normal maturation of all series, but also 25% mature plasma cells. RT-PCR did not detect any BCR/ABL mRNA transcripts. Cytogenetic analysis revealed the absence of the Ph¹ chromosome and no additional abnormalities. Laboratory values were within normal limits and a skeletal survey showed no lytic lesions. Using nephelometry, IgG levels were 2,340 mg/dl (normal range, 751–1,560 mg/dl) and light chains levels were 2,450 mg/dl (normal range, 313–723 mg/dl), without depression of the other immunoglobulins. One month later, examination of a new bone marrow smear revealed that mature plasma cells rose to 45%, while a bone marrow aspirate disclosed diffuse bone marrow infiltration by plasma cells that were shown to be light chain positive with immunoperoxidase staining. The patient was treated with melphalan (Alkeran^®; GlaxoSmithKline, Philadelphia, http://www.gsk.com) and prednisone (Deltasone^®; Pfizer Pharmaceuticals, New York, http://www.pfizer.com); imatinib was continued. Eight months later, a bone marrow aspirate showed normal findings (plasma cells 1.5%) and so did nephelometry.

The chromosomal abnormality detected in our patient is a complex Ph¹ chromosome containing translocations between chromosomes 9, 14, and 22 and involves the locus of the light chain (22q11). This abnormality might have triggered the development of the two distinct hematologic malignancies: CML and IgG MM.

Our patient developed MM after 7 months of treatment with imatinib mesylate. Whether the development of MM was spontaneous or accelerated by imatinib is difficult to prove. Recently, imatinib has been shown to inhibit proliferation of MM cells in vitro by arresting cell-cycle progression; furthermore, it inhibited the proliferation of MM cells resistant to dexamethasone (Decadron^®; Merck and Co., Inc., Whitehouse Station, NJ, http://www.merck.com) or melphalan and had an additive effect when combined with dexamethasone. Nevertheless, imatinib also exhibited a small stimulatory effect on the proliferation of MM cells through activation of the Erk1/2 mitogen-activated protein kinases route [4]. Existence of causality between the treatment with imatinib and development of MM cannot be ruled out.

Imatinib has revolutionized the treatment of CML, but experience with its use is still limited. Even though there is no evidence that administration of imatinib could result in the development of MM, vigilance should be shown in order to promptly identify potential side effects of this novel agent.

	DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Top Disclosure of Potential... References

 
The authors have indicated no potential conflicts of interest.

	REFERENCES

Top Disclosure of Potential... References

 

1. Nitta M, Tsuboi K, Yamashita S et al. Multiple myeloma preceding the development of chronic myelogenous leukemia. Int J Hematol 1999;69:170–173.[Medline]
2. Tanaka M, Kimura R, Matsutani A et al. Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature. Acta Haematol 1998;99:221–223.[Medline]
3. Peggs K, Mackinnon S. Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048–1050.[Free Full Text]
4. Pandiella A, Carvajal-Vergara X, Tabera S et al. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 2003;123:858–868.[CrossRef][Medline]

This article has been cited by other articles:

				M. Michael, M. Antoniades, E. Lemesiou, N. Papaminas, and F. Melanthiou Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months Oncologist, December 1, 2009; 14(12): 1198 - 1200. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garipidou, V. Articles by Tziomalos, K. Search for Related Content PubMed PubMed Citation Articles by Garipidou, V. Articles by Tziomalos, K.